Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Jun 15;101(12):2831–2841. doi: 10.1172/JCI1880

Therapeutic levels of human protein C in rats after retroviral vector-mediated hepatic gene therapy.

S R Cai 1, S C Kennedy 1, W M Bowling 1, M W Flye 1, K P Ponder 1
PMCID: PMC508874  PMID: 9637717

Abstract

Protein C deficiency results in a thrombotic disorder that might be treated by expressing a normal human protein C (hPC) gene in patients. An amphotropic retroviral vector with a liver-specific promoter and the hPC cDNA was delivered to rat hepatocytes in vivo during liver regeneration. Expression of hPC varied from 55 to 203 ng/ml (1.3-5.0% of normal) for 2 wk after transduction. Expression increased to an average of 900 ng/ml (22% of normal) in some rats and was maintained at stable levels for 1 yr. All of these rats developed anti-hPC antibodies and exhibited a prolonged hPC half-life in vivo. The hPC was functional as determined by a chromogenic substrate assay after immunoprecipitation. We conclude that most rats achieved hPC levels that would prevent purpura fulminans, and that hepatic gene therapy might become a viable treatment for patients with severe homozygous hPC deficiency. Anti-hPC antibodies increased the hPC half-life and plasma levels in some rats, but did not interfere with its functional activity. Thus, the development of antibodies against a plasma protein does not necessarily abrogate its biological effect in gene therapy experiments.

Full Text

The Full Text of this article is available as a PDF (323.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aiach M., Gandrille S., Emmerich J. A review of mutations causing deficiencies of antithrombin, protein C and protein S. Thromb Haemost. 1995 Jul;74(1):81–89. [PubMed] [Google Scholar]
  2. Auberger K. Evaluation of a new protein-C concentrate and comparison of protein-C assays in a child with congenital protein-C deficiency. Ann Hematol. 1992 Mar;64(3):146–151. doi: 10.1007/BF01697402. [DOI] [PubMed] [Google Scholar]
  3. BERSON S. A., YALOW R. S., BAUMAN A., ROTHSCHILD M. A., NEWERLY K. Insulin-I131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects. J Clin Invest. 1956 Feb;35(2):170–190. doi: 10.1172/JCI103262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baliga V., Thwaites R., Tillyer M. L., Minford A., Parapia L., Allgrove J. Homozygous protein C deficiency--management with protein C concentrate. Eur J Pediatr. 1995 Jul;154(7):534–538. doi: 10.1007/BF02074829. [DOI] [PubMed] [Google Scholar]
  5. Batlle J., Gómez E., Rendal E., Torea J., Lourés E., Couselo M., Vila P., Sedano C., Tusell X., Magallón M. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects. Ann Hematol. 1996 May;72(5):321–326. doi: 10.1007/s002770050179. [DOI] [PubMed] [Google Scholar]
  6. Bosch A., McCray P. B., Jr, Chang S. M., Ulich T. R., Simonet W. S., Jolly D. J., Davidson B. L. Proliferation induced by keratinocyte growth factor enhances in vivo retroviral-mediated gene transfer to mouse hepatocytes. J Clin Invest. 1996 Dec 15;98(12):2683–2687. doi: 10.1172/JCI119091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bowles N. E., Eisensmith R. C., Mohuiddin R., Pyron M., Woo S. L. A simple and efficient method for the concentration and purification of recombinant retrovirus for increased hepatocyte transduction in vivo. Hum Gene Ther. 1996 Sep 10;7(14):1735–1742. doi: 10.1089/hum.1996.7.14-1735. [DOI] [PubMed] [Google Scholar]
  8. Bowling W. M., Kennedy S. C., Cai S. R., Duncan J. R., Gao C., Flye M. W., Ponder K. P. Portal branch occlusion safely facilitates in vivo retroviral vector transduction of rat liver. Hum Gene Ther. 1996 Nov 10;7(17):2113–2121. doi: 10.1089/hum.1996.7.17-2113. [DOI] [PubMed] [Google Scholar]
  9. Branson H. E., Katz J., Marble R., Griffin J. H. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet. 1983 Nov 19;2(8360):1165–1168. doi: 10.1016/s0140-6736(83)91216-3. [DOI] [PubMed] [Google Scholar]
  10. Brownlee G. G. Prospects for gene therapy of haemophilia A and B. Br Med Bull. 1995 Jan;51(1):91–105. doi: 10.1093/oxfordjournals.bmb.a072956. [DOI] [PubMed] [Google Scholar]
  11. Casella J. F., Lewis J. H., Bontempo F. A., Zitelli B. J., Markel H., Starzl T. E. Successful treatment of homozygous protein C deficiency by hepatic transplantation. Lancet. 1988 Feb 27;1(8583):435–438. doi: 10.1016/s0140-6736(88)91231-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cassels-Brown A., Minford A. M., Chatfield S. L., Bradbury J. A. Ophthalmic manifestations of neonatal protein C deficiency. Br J Ophthalmol. 1994 Jun;78(6):486–487. doi: 10.1136/bjo.78.6.486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Conard J., Bauer K. A., Gruber A., Griffin J. H., Schwarz H. P., Horellou M. H., Samama M. M., Rosenberg R. D. Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. Blood. 1993 Aug 15;82(4):1159–1164. [PubMed] [Google Scholar]
  14. Connelly S., Gardner J. M., McClelland A., Kaleko M. High-level tissue-specific expression of functional human factor VIII in mice. Hum Gene Ther. 1996 Jan 20;7(2):183–195. doi: 10.1089/hum.1996.7.2-183. [DOI] [PubMed] [Google Scholar]
  15. Connelly S., Mount J., Mauser A., Gardner J. M., Kaleko M., McClelland A., Lothrop C. D., Jr Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood. 1996 Nov 15;88(10):3846–3853. [PubMed] [Google Scholar]
  16. Connelly S., Smith T. A., Dhir G., Gardner J. M., Mehaffey M. G., Zaret K. S., McClelland A., Kaleko M. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum Gene Ther. 1995 Feb;6(2):185–193. doi: 10.1089/hum.1995.6.2-185. [DOI] [PubMed] [Google Scholar]
  17. Dai Y., Roman M., Naviaux R. K., Verma I. M. Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10892–10895. doi: 10.1073/pnas.89.22.10892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Dai Y., Schwarz E. M., Gu D., Zhang W. W., Sarvetnick N., Verma I. M. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1401–1405. doi: 10.1073/pnas.92.5.1401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Dixon K., Exon P. D., Malins J. M. Insulin antibodies and the control of diabetes. Q J Med. 1975 Oct;44(176):543–553. [PubMed] [Google Scholar]
  20. Dreyfus M., Masterson M., David M., Rivard G. E., Müller F. M., Kreuz W., Beeg T., Minford A., Allgrove J., Cohen J. D. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost. 1995;21(4):371–381. doi: 10.1055/s-2007-1000658. [DOI] [PubMed] [Google Scholar]
  21. España F., Vicente V., Tabernero D., Scharrer I., Griffin J. H. Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. Thromb Res. 1990 Aug 1;59(3):593–608. doi: 10.1016/0049-3848(90)90418-c. [DOI] [PubMed] [Google Scholar]
  22. Estellés A., Garcia-Plaza I., Dasí A., Aznar J., Duart M., Sanz G., Pérez-Requejo J. L., España F., Jimenez C., Abeledo G. Severe inherited "homozygous" protein C deficiency in a newborn infant. Thromb Haemost. 1984 Aug 31;52(1):53–56. [PubMed] [Google Scholar]
  23. Foster D., Davie E. W. Characterization of a cDNA coding for human protein C. Proc Natl Acad Sci U S A. 1984 Aug;81(15):4766–4770. doi: 10.1073/pnas.81.15.4766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Garcia-Plaza I., Jimenez-Astorga C., Borrego D., Marty M. L. Coumarin prophylaxis for fulminant purpura syndrome due to homozygous protein C deficiency. Lancet. 1985 Mar 16;1(8429):634–635. doi: 10.1016/s0140-6736(85)92167-1. [DOI] [PubMed] [Google Scholar]
  25. Garver R. I., Jr, Chytil A., Karlsson S., Fells G. A., Brantly M. L., Courtney M., Kantoff P. W., Nienhuis A. W., Anderson W. F., Crystal R. G. Production of glycosylated physiologically "normal" human alpha 1-antitrypsin by mouse fibroblasts modified by insertion of a human alpha 1-antitrypsin cDNA using a retroviral vector. Proc Natl Acad Sci U S A. 1987 Feb;84(4):1050–1054. doi: 10.1073/pnas.84.4.1050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Hafenrichter D. G., Wu X., Rettinger S. D., Kennedy S. C., Flye M. W., Ponder K. P. Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes. Blood. 1994 Nov 15;84(10):3394–3404. [PubMed] [Google Scholar]
  27. Hartman K. R., Manco-Johnson M., Rawlings J. S., Bower D. J., Marlar R. A. Homozygous protein C deficiency: early treatment with warfarin. Am J Pediatr Hematol Oncol. 1989 Winter;11(4):395–401. [PubMed] [Google Scholar]
  28. Herzog R. W., Hagstrom J. N., Kung S. H., Tai S. J., Wilson J. M., Fisher K. J., High K. A. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A. 1997 May 27;94(11):5804–5809. doi: 10.1073/pnas.94.11.5804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Jainchill J. L., Aaronson S. A., Todaro G. J. Murine sarcoma and leukemia viruses: assay using clonal lines of contact-inhibited mouse cells. J Virol. 1969 Nov;4(5):549–553. doi: 10.1128/jvi.4.5.549-553.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Katsuura Y., Mochizuki T., Tamura M., Hoshide S., Kiyoki M., Nakagaki T., Miyamoto S. Species specificity of anticoagulant activity of activated human protein C: involvement of factor V as well as protein S. Thromb Res. 1996 Apr 15;82(2):147–157. doi: 10.1016/0049-3848(96)00061-8. [DOI] [PubMed] [Google Scholar]
  31. Kay M. A., Landen C. N., Rothenberg S. R., Taylor L. A., Leland F., Wiehle S., Fang B., Bellinger D., Finegold M., Thompson A. R. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2353–2357. doi: 10.1073/pnas.91.6.2353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Kay M. A., Rothenberg S., Landen C. N., Bellinger D. A., Leland F., Toman C., Finegold M., Thompson A. R., Read M. S., Brinkhous K. M. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science. 1993 Oct 1;262(5130):117–119. doi: 10.1126/science.8211118. [DOI] [PubMed] [Google Scholar]
  33. Koster T., Rosendaal F. R., Briët E., van der Meer F. J., Colly L. P., Trienekens P. H., Poort S. R., Reitsma P. H., Vandenbroucke J. P. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study) Blood. 1995 May 15;85(10):2756–2761. [PubMed] [Google Scholar]
  34. Kotani H., Newton P. B., 3rd, Zhang S., Chiang Y. L., Otto E., Weaver L., Blaese R. M., Anderson W. F., McGarrity G. J. Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther. 1994 Jan;5(1):19–28. doi: 10.1089/hum.1994.5.1-19. [DOI] [PubMed] [Google Scholar]
  35. Kozak M. Structural features in eukaryotic mRNAs that modulate the initiation of translation. J Biol Chem. 1991 Oct 25;266(30):19867–19870. [PubMed] [Google Scholar]
  36. Le M., Okuyama T., Cai S. R., Kennedy S. C., Bowling W. M., Flye M. W., Ponder K. P. Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy. Blood. 1997 Feb 15;89(4):1254–1259. [PubMed] [Google Scholar]
  37. Lozier J. N., Brinkhous K. M. Gene therapy and the hemophilias. JAMA. 1994 Jan 5;271(1):47–51. [PubMed] [Google Scholar]
  38. Marciniak E., Wilson H. D., Marlar R. A. Neonatal purpura fulminans: a genetic disorder related to the absence of protein C in blood. Blood. 1985 Jan;65(1):15–20. [PubMed] [Google Scholar]
  39. Markowitz D., Goff S., Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology. 1988 Dec;167(2):400–406. [PubMed] [Google Scholar]
  40. McAdams G. B., Knox K. R., Wilcox D. S. The initial, rapid-phase disappearance of intravenous radioinsulin in diabetes. J Nucl Med. 1967 Mar;8(3):173–178. [PubMed] [Google Scholar]
  41. Miletich J., Sherman L., Broze G., Jr Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med. 1987 Oct 15;317(16):991–996. doi: 10.1056/NEJM198710153171604. [DOI] [PubMed] [Google Scholar]
  42. Miller A. D., Rosman G. J. Improved retroviral vectors for gene transfer and expression. Biotechniques. 1989 Oct;7(9):980-2, 984-6, 989-90. [PMC free article] [PubMed] [Google Scholar]
  43. Minford A. M., Parapia L. A., Stainforth C., Lee D. Treatment of homozygous protein C deficiency with subcutaneous protein C concentrate. Br J Haematol. 1996 Apr;93(1):215–216. doi: 10.1046/j.1365-2141.1996.4691021.x. [DOI] [PubMed] [Google Scholar]
  44. Mohanty D., al Hassan H., Neglen P., Eklof B., Das K. C. Protein C deficiency in Kuwait. J Lab Clin Med. 1995 Oct;126(4):373–376. [PubMed] [Google Scholar]
  45. Müller F. M., Ehrenthal W., Hafner G., Schranz D. Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate. Eur J Pediatr. 1996 Jan;155(1):20–25. doi: 10.1007/BF02115621. [DOI] [PubMed] [Google Scholar]
  46. Okuyama T., Huber R. M., Bowling W., Pearline R., Kennedy S. C., Flye M. W., Ponder K. P. Liver-directed gene therapy: a retroviral vector with a complete LTR and the ApoE enhancer-alpha 1-antitrypsin promoter dramatically increases expression of human alpha 1-antitrypsin in vivo. Hum Gene Ther. 1996 Mar 20;7(5):637–645. doi: 10.1089/hum.1996.7.5-637. [DOI] [PubMed] [Google Scholar]
  47. PROUT T. E., KATIMS R. B. The effect of insulin-binding serum globulin on insulin requirement. Diabetes. 1959 Nov-Dec;8:425–431. doi: 10.2337/diab.8.6.425. [DOI] [PubMed] [Google Scholar]
  48. Pastores G. M., Sibille A. R., Grabowski G. A. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood. 1993 Jul 15;82(2):408–416. [PubMed] [Google Scholar]
  49. Perales J. C., Ferkol T., Beegen H., Ratnoff O. D., Hanson R. W. Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4086–4090. doi: 10.1073/pnas.91.9.4086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Pescatore P., Horellou H. M., Conard J., Piffoux M., Van Dreden P., Ruskone-Fourmestraux A., Samama M. Problems of oral anticoagulation in an adult with homozygous protein C deficiency and late onset of thrombosis. Thromb Haemost. 1993 Apr 1;69(4):311–315. [PubMed] [Google Scholar]
  51. Ponce E., Moskovitz J., Grabowski G. Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase. Blood. 1997 Jul 1;90(1):43–48. [PubMed] [Google Scholar]
  52. Reitsma P. H., Bernardi F., Doig R. G., Gandrille S., Greengard J. S., Ireland H., Krawczak M., Lind B., Long G. L., Poort S. R. Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1995 May;73(5):876–889. [PubMed] [Google Scholar]
  53. Rettinger S. D., Kennedy S. C., Wu X., Saylors R. L., Hafenrichter D. G., Flye M. W., Ponder K. P. Liver-directed gene therapy: quantitative evaluation of promoter elements by using in vivo retroviral transduction. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1460–1464. doi: 10.1073/pnas.91.4.1460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Richards S. M., Olson T. A., McPherson J. M. Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood. 1993 Sep 1;82(5):1402–1409. [PubMed] [Google Scholar]
  55. Seligsohn U., Berger A., Abend M., Rubin L., Attias D., Zivelin A., Rapaport S. I. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med. 1984 Mar 1;310(9):559–562. doi: 10.1056/NEJM198403013100904. [DOI] [PubMed] [Google Scholar]
  56. Sharon C., Tirindelli M. C., Mannucci P. M., Tripodi A., Mariani G. Homozygous protein C deficiency with moderately severe clinical symptoms. Thromb Res. 1986 Feb 15;41(4):483–488. doi: 10.1016/0049-3848(86)91693-2. [DOI] [PubMed] [Google Scholar]
  57. Sills R. H., Marlar R. A., Montgomery R. R., Deshpande G. N., Humbert J. R. Severe homozygous protein C deficiency. J Pediatr. 1984 Sep;105(3):409–413. doi: 10.1016/s0022-3476(84)80013-x. [DOI] [PubMed] [Google Scholar]
  58. Smith T. A., Mehaffey M. G., Kayda D. B., Saunders J. M., Yei S., Trapnell B. C., McClelland A., Kaleko M. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet. 1993 Dec;5(4):397–402. doi: 10.1038/ng1293-397. [DOI] [PubMed] [Google Scholar]
  59. Snyder R. O., Miao C. H., Patijn G. A., Spratt S. K., Danos O., Nagy D., Gown A. M., Winther B., Meuse L., Cohen L. K. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet. 1997 Jul;16(3):270–276. doi: 10.1038/ng0797-270. [DOI] [PubMed] [Google Scholar]
  60. Soriano P., Montgomery C., Geske R., Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell. 1991 Feb 22;64(4):693–702. doi: 10.1016/0092-8674(91)90499-o. [DOI] [PubMed] [Google Scholar]
  61. St Louis D., Verma I. M. An alternative approach to somatic cell gene therapy. Proc Natl Acad Sci U S A. 1988 May;85(9):3150–3154. doi: 10.1073/pnas.85.9.3150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Suzuki K., Deyashiki Y., Nishioka J., Toma K. Protein C inhibitor: structure and function. Thromb Haemost. 1989 Jun 30;61(3):337–342. [PubMed] [Google Scholar]
  63. Sweetser D. A., Birkenmeier E. H., Klisak I. J., Zollman S., Sparkes R. S., Mohandas T., Lusis A. J., Gordon J. I. The human and rodent intestinal fatty acid binding protein genes. A comparative analysis of their structure, expression, and linkage relationships. J Biol Chem. 1987 Nov 25;262(33):16060–16071. [PubMed] [Google Scholar]
  64. Takano K., Shizume K., Hizuka N., Okuno A., Umino T., Kobayashi Y., Kusano S., Nakajima H., Irie M., Hibi I. Treatment of pituitary dwarfism with methionyl human growth hormone in Japan. Endocrinol Jpn. 1986 Oct;33(5):589–596. doi: 10.1507/endocrj1954.33.589. [DOI] [PubMed] [Google Scholar]
  65. Thompson A. R. Progress towards gene therapy for the hemophilias. Thromb Haemost. 1995 Jul;74(1):45–51. [PubMed] [Google Scholar]
  66. Walter J., You Q., Hagstrom J. N., Sands M., High K. A. Successful expression of human factor IX following repeat administration of adenoviral vector in mice. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3056–3061. doi: 10.1073/pnas.93.7.3056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Wang J. M., Zheng H., Blaivas M., Kurachi K. Persistent systemic production of human factor IX in mice by skeletal myoblast-mediated gene transfer: feasibility of repeat application to obtain therapeutic levels. Blood. 1997 Aug 1;90(3):1075–1082. [PubMed] [Google Scholar]
  68. Yao S. N., Kurachi K. Expression of human factor IX in mice after injection of genetically modified myoblasts. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3357–3361. doi: 10.1073/pnas.89.8.3357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Yuen P., Cheung A., Lin H. J., Ho F., Mimuro J., Yoshida N., Aoki N. Purpura fulminans in a Chinese boy with congenital protein C deficiency. Pediatrics. 1986 May;77(5):670–676. [PubMed] [Google Scholar]
  70. van der Meer F. J., van Tilburg N. H., van Wijngaarden A., van der Linden I. K., Briët E., Bertina R. M. A second plasma inhibitor of activated protein C: alpha 1-antitrypsin. Thromb Haemost. 1989 Sep 29;62(2):756–762. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES